Please ensure Javascript is enabled for purposes of website accessibility

Altered states

Once considered a criminal enterprise, the cannabis landscape continues to evolve rapidly, as a growing number of nations1 and US states move to legalize the mind-altering2 drug for medicinal and recreational purposes. However, within the US, despite the many states that have decriminalized marijuana, the drug remains federally illegal. Under the Controlled Substances Act, marijuana is currently classified as a Schedule 1 drug—deemed to have no accepted medical applications3. Its status as a controlled substance at the federal level poses the primary headwind for emergent business models within the industry for both recreational and medicinal players. However, momentum is building in Washington DC, as US lawmakers consider easing federal regulations and allowing financial institutions to offer services to the cannabis industry without the risk of repercussions. While the emerging legal landscape of the cannabis industry faces a unique set of challenges, it also presents a myriad of opportunities. Research efforts are under way to provide health care providers and payers with data sets supporting the efficacy of medical marijuana products, which could transform the industry. Whether for medicinal or recreational purposes, cannabis is becoming increasingly mainstream4 as more people are finding ways to incorporate it into their everyday lives.

Raphael J. Lewis and Jack Encarnacao, research analysts at Newton Investment Management


1BBC News. Why are so many countries now saying cannabis is OK? December 11, 2018.
2Department of Justice/Drug Enforcement Administration. Drug fact sheet. Marijuana/cannabis. April 2020.
4Gallup. Nearly half of US adults have tried marijuana. August 17, 2021.


All investments involve some level of risk, including loss of principal. Certain investments have specific or unique risks. Any views and opinions are those of the investment manager, unless otherwise noted and is not investment advice.

Recent market risks include pandemic risks related to COVID-19. The effects of COVID-19 have contributed to increased volatility in global markets and will likely affect certain countries, companies, industries and market sectors more dramatically than others.

This material has been provided for informational purposes only and should not be construed as tax advice, investment advice or a recommendation of any particular investment product, strategy, investment manager or account arrangement, and should not serve as a primary basis for investment decisions. Prospective investors should consult a legal, tax or financial professional in order to determine whether any investment product, strategy or service is appropriate for their particular circumstances. Views expressed are those of the author stated and do not reflect views of other managers or the firm overall. Views are current as of the date of this publication and subject to change.
This information contains projections or other forward-looking statements regarding future events, targets or expectations, and is only current as of the date indicated. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. References to specific securities, asset classes and financial markets are for illustrative purposes only and are not intended to be and should not be interpreted as recommendations. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.

BNY Mellon Investment Management is one of the world’s leading investment management organizations, encompassing BNY Mellon’s affiliated investment management firms and global distribution companies. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may also be used as a generic term to reference the corporation as a whole or its various subsidiaries generally.

“Newton” and/or the “Newton Investment Management” brand refers to the following group of affiliated companies: Newton Investment Management Limited (NIM) and Newton Investment Management North America LLC (NIMNA). NIM is incorporated in the United Kingdom (Registered in England no. 1371973) and is authorized and regulated by the Financial Conduct Authority in the conduct of investment business. Both Newton firms are registered with the Securities and Exchange Commission (SEC) in the United States of America as an investment adviser under the Investment Advisers Act of 1940. Newton is a subsidiary of The Bank of New York Mellon Corporation. Newton’s investment advisory businesses are described in their Form ADVs, Part 1 and 2, which can be obtained from the website or obtained upon request.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission.

Not FDIC-Insured | No Bank Guarantee | May Lose Value

©2022 BNY Mellon Securities Corporation, distributor, 240 Greenwich St., New York, NY 10286.